Abstract: Despite the finding that rtL180M and rtM204V/I were higher among ART-experienced individuals, the overall prevalence of DRMs (48.0% versus 36.4%) showed no significance difference among antiretroviral therapy (ART) status.
Abstract: Lamivudine selected DRMs, that is, rtL180M (29.3%) and rtM204V/I (29.3%) and rtV173L (15.5%) were more prevalent in HBV-HIV-coinfected individuals but absent in HBV-monoinfected individuals.
Abstract: RESULTS: In 34 out of 161 study subjects (21.1%) HBV drug resistance mutations (DRM
HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Introduction: However, it has been shown that HBV resistance to 3TC occurs rapidly through the rtM204V/I substitutions.
Discussion: <
Discussion: In our study, twenty (95.2%) of the 21 patients had at least one mutation that may confer clinical resistance to both telbivudine (rtM204V/I) and 3TC (rt180M + rtM204V/I, rtV173L + rtL180M + rtM204V/I, and rtL80I + rtM204I).
Overt and occult hepatitis B virus infection among treatment-naive HIV-infected patients in Brazil.
Abstract: One patient had the M204I and L180M drug-resistance mutations (polymerase).
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).
PMID: 26136470
2016
The Journal of infectious diseases
Abstract: The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%).
Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultradeep pyrosequencing.
Result: Although all 12 patients experienced viral breakthrough during the treatment with LAM, low rates of drug resistance-associated mutations were observed at week 0 prior to the treatment, with the exception of patient D, who exhibited a rate of 94.03 for M204I, and patient G, who exhibited a rate of 97.59 for A181V.
Result: Furthermore, the increased mutation rate of rt180 or rt80 was accompanied by the occurrence of the high mutation rate of M204I during the virological breakthrough.
Result: Notably, the mutation rate of rtM204I/V was markedly increased at the time of virological breakthrough in eight patients, and this was accompanied by an increased mutation rate of rt
Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.
Abstract: The mutation M204V/I conferring resistance to 3TC was more common in HBV/A (47.4%) than in HBV/E isolates (0%) (P = .04).
Introduction: Regarding HBV mutations, the use of 3TC alone has been shown to be strongly associated with consistently high HBV viremia due to the rapid emergence of HBV mutants carrying the M204I/V mutation conferring resistance to 3TC/FTC.
Method: Using the Mutation Reporter Tool software (http://hvdr.bioinf.wits.ac.za/mrt/), HBV resistance-associated mutations (RAMs) in the pol gene represented by
Result: Regarding RAMs, the mutation M204V/I, associated with the compensatory mutation L180M, was significantly more common in genotype HBV/A (9/19, 47.4%) than in genotype HBV/E (0/9, 0%) (Yate's corrected chi2, P = .04) (Fig 6, Table 2).
Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.
Discussion: In the present study, 7 patients harbored the rtL180 M, rtS202G, and rtM204I/V substitutions at a frequency of >1% at baseline, 5 of these patients belonged to the PVR group, and the other 2 belonged to the CVR group.
Discussion: One study reported that the most commonly detected mutations were M204 V/I, M250 V/I, A181T/V, and N236T.
Discussion: UDPS indicated that NAr mutations were pre-existent at low percentages (ranging from 0.1% to 6.7%) at baseline, including rtV173A/M, rt
Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone.
PMID: 26831605
2016
Saudi journal of gastroenterology
Discussion: Newly developed HBV rtM204I and rtP237H mutants were detected, and the pre-existing HBV rtA181V mutant disappeared completely through rescue therapy.
Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China.
PMID: 26876337
2016
The Brazilian journal of infectious diseases
Abstract: Mutations in HBV DNA polymerase were detected in 24 patients (8.9%) including rtM204I/V (n=6), rtN236T (n=5), rtM250V (n=2), rtL180M (n=2), rtT184G (n=1), rtM207I (n=1), rtS202I (n=1), rtM204V/I & rtL180M (n=5), and rtM204I &
HBV mutation literature information.
PMID: 
2017
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT